NASD · Healthcare · Medical Devices · USA
NeuroPace Inc is a micro cap company (market value under $300 million) in the Medical Devices industry.
NeuroPace develops the RNS System, a brain-responsive neuromodulation device for treating drug-resistant focal epilepsy in adults. The system continuously monitors brain electrical activity, recognizes abnormal patterns, and delivers targeted electrical stimulation at the seizure source to prevent seizures. The company markets its device to epileptologists and neurosurgeons through a direct sales organization in the United States.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the NeuroPace Inc stock.
Overvalued: intrinsic value $0.22 per share, market price $8.20, margin of safety -3647.2% (as of 2026-11-17).
Its liquidation floor, current assets minus every liability, values the shares at $0.22; the price of $8.20 is 3647% above that value.
15 more funds hold it; the full list is part of the paid plan.
All 140 Medical Devices stocks
60 more in this industry show a wider margin of safety.
NPCE is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $0.22; the price of $8.20 is 3647% above that value.
$0.22 per share (as of the 2026-11-17 close), against a market price of $8.20. That is a margin of safety of -3647.2%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.